NKG2A blockade as a standalone therapy has appeared poorly effective in mouse tumor models; however, in the presence of activated T cells, for example, induced by PD-1/PD-L1 blockade, it exerts strongly enhanced efficacy. Here, KLRC1 is linked to neoplasm.